GlassScriptPhysician profile
Brandy M Protz
NPI 1508445511
$2,455.22
in general payments reported to CMS, 2019-2025
25 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.59 · 2022: $70.78 · 2023: $618 · 2024: $635 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.58 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.49 | 2022-2025 | |
| Novo Nordisk INC | $497.19 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $109.12 | 2023-2025 | |
| Corcept Therapeutics | $84.78 | 2024-2025 | Korlym |
| Neos Therapeutics, LP | $84.58 | 2023-2025 | Adzenys Xr-Odt |
| Lilly USA, LLC | $81.06 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $77.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.67 | 2021-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $74.80 | 2023-2025 | Strensiq |
| Axsome Therapeutics, INC. | $61.77 | 2024-2025 | Auvelity |
| Ibsa Pharma INC. | $57.65 | 2023-2025 | Tirosint, Licart, Tirosint |
| Hologic Sales and Service, LLC | $40.57 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Phathom Pharmaceuticals, INC. | $38.81 | 2024 | Voquezna |
| Astellas Pharma US INC | $34.52 | 2025 | Veozah |
| Abbott Laboratories | $33.83 | 2025 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $27.49 | 2022 | |
| Amneal Pharmaceuticals LLC | $27.44 | 2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $27.16 | 2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.68 | 2021 | |
| Ironshore Pharmaceuticals INC. | $20.83 | 2024 | |
| Idorsia Pharmaceuticals US INC | $20.05 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $18.52 | 2025 | Nexletol |
| Currax Pharmaceuticals LLC | $16.91 | 2024 | Contrave |
| Biosense Webster, INC. | $14.42 | 2025 | Soundstar, Nuvision Ice Catheter |
| Acella Pharmaceuticals, LLC | $12.99 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Protz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.